Questionnaire | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | |
Y | Y | Y | Y | Y | Y | Y | Y | # | P | ||||
Collection begins January 1, 2022. | Y | ||||||||||||
Y | Y | ^ | |||||||||||
MR | |||||||||||||
Y | |||||||||||||
Y | |||||||||||||
Y | |||||||||||||
Y | |||||||||||||
Y | |||||||||||||
Y | |||||||||||||
Y | |||||||||||||
LLS | |||||||||||||
Y | |||||||||||||
*Form 521 in WHI started 6/22/2015 with a one-time administration. | Y | ||||||||||||
Questionnaire | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
Questionnaire | 2005 | 2006 | 2007 | 2008 | 2009 |
---|---|---|---|---|---|
Y | Y | Y | Y | Y | |
If an event that needed adjudication was found on the form 33, a 33D was collected. | |||||
HT | HT | ||||
Y | |||||
HT | HT | HT | HT | HT | |
Y | Y | Y | Y | Y | |
Y | |||||
*All participants who previously reported diagnosis of breast cancer | % |
Questionnaire | Baseline | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | Closeout |
---|---|---|---|---|---|---|---|---|---|---|---|
Y | |||||||||||
HT | |||||||||||
HT | HT | HT | HT | HT | HT | HT | HT | HT | HT | ||
CaD | CaD | CaD | CaD | CaD | CaD | CaD | CaD | CaD | CaD | ||
Y | |||||||||||
*For E+P, when intervention stopped July 9, 2002. For E-Alone, when intervention stopped in February 2004. | HT | ||||||||||
*At CaD study close-out October 2004-March 2005. | CaD | ||||||||||
Y | |||||||||||
Y | |||||||||||
Y | |||||||||||
Collected every 6 months for HT ppts | Y | Y | Y | Y | Y | Y | Y | Y | Y | CT | |
If an event that needed adjudication was found on the form 33, a 33D was collected. | |||||||||||
Y | |||||||||||
CT | CT | CT | CT | ||||||||
Y | CT | ||||||||||
CT | CT%/OS | CT% | CT% | ||||||||
*HT cohort aged 65 and over. | HT% | HT% | HT% | HT% | HT% | ||||||
Y | |||||||||||
*Initiated in 2002 and collected once from all CT and OS participants at next routine contact. | |||||||||||
OS | |||||||||||
Y | |||||||||||
Y | CT | Y | CT | CT | |||||||
Y | CT | Y | CT | CT | |||||||
OS | |||||||||||
*For E+P participants on study through July 8, 2002, when intervention was stopped; administration began in March 2003. | |||||||||||
entered if ppt needed to modify their study medication dosage | |||||||||||
*For all E-Alone participants; administered twice: | |||||||||||
*Year 2: 30% cross sectional 33% rotating subsample starting in the year 2000, such that for year 3 and each subsequent year each DM participant received an FFQ at once every 3 years. | Y | DM | DM% | DM%/OS | DM% | DM% | DM% | DM% | DM% | DM% | |
Y | CT | CT | Y | CT | CT | CT | CT | CT | CT | ||
Y | HT | HT | HT | HT | HT | HT | HT | HT | HT | ||
Administered as indicated and as needed to manage unexpected bleeding. Not required after July 9, 2002, when intervention was stopped. *5% E+P participants with uterus | HT | HT% | HT% | HT% | |||||||
*Done only if endometrial aspiration could not be done or was refused. | |||||||||||
*Optional for DM participants. | Y | HT | HT | HT | HT | HT | HT | HT | HT | HT | |
Y | HT | HT | HT | HT | HT | HT | HT | HT | HT | HT | |
CT | CT | CT | CT | ||||||||
*Collected for ppts enrolled at 3 clinical centers or about 6-7% of total WHI. Yr1 collection limited to CT | % | % | % | % | % | ||||||
*Sample was selected from the HT and DM > 65 years old. | CT% | CT% | CT% | CT% | |||||||
Y | |||||||||||
*6% CT subsample. Year 6 collection was plasma only | Y | CT | CT%/OS | CT% | CT% | ||||||
*% - Collected at 3 BMD clinical centers. Year 9 collection was for 25% of OS ppts | CT/OS% | CT% | CT/OS% | CT% | OS% | ||||||
OS | |||||||||||
OS | |||||||||||
OS | |||||||||||
OS | |||||||||||
OS | |||||||||||
OS | |||||||||||
*For OS participants who did not reach Year 7 by Closeout | OS | ||||||||||
Questionnaire | Baseline | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | Closeout |